Testing chemo after hormone therapy in premenopausal early breast cancer
Part of Cancer, Skin clinical trials.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can sign the informed consent paperwork before starting study steps
- You are female and at least 18 years old, and still have signs of active ovaries (premenopausal)
- Your daily functioning is fairly good: ECOG 0–2 (or Karnofsky score 60% or higher)
- Your breast cancer is ER-positive and/or progesterone-receptor positive, and HER2-negative
- Your lymph node findings and tumor stage fit the study: no clear spread to distant organs, and specific pN0–pN1 patterns
- Your Oncotype DX recurrence score fits the study ranges (about 16–25 depending on node status)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial compares hormone-based treatment versus chemotherapy given before surgery in people who are premenopausal and have hormone-receptor positive, HER2-negative breast cancer. It looks to see which approach works better to control the cancer before the breast operation.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests if giving hormone-blocking pills before surgery can help guide which treatments you need after surgery. It is for premenopausal women with early-stage, hormone-sensitive breast cancer.
This trial is testing how well a short course of hormone-blocking pills (endocrine therapy) works before surgery in women with early-stage hormone receptor-positive HER2-negative breast cancer. The goal is to understand what makes some cancers resistant to these treatments.
This trial tests if women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy after surgery by taking targeted medication (ribociclib) plus hormone therapy. A special blood test called ctDNA helps doctors decide if chemo isn't needed.
This Phase 2 trial studies whether women with very low-risk, hormone-receptor positive breast cancer can safely take hormone therapy for a shorter time. It may help reduce side effects if shorter treatment works as well as the longer standard plan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.